GlassScriptPhysician profile
Deirdre Jocelyn James
NPI 1033552492
$1,787.08
in general payments reported to CMS, 2019-2025
16 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.32 · 2021: $20.07 · 2022: $287 · 2023: $201 · 2024: $565 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $529.49 | 2022-2025 | |
| Sk Life Science, INC. | $278.97 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $251.31 | 2023-2024 | Strensiq, Ultomiris, Soliris |
| Sequel Med Tech, LLC | $147.13 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $123.36 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $113.13 | 2022-2025 | |
| Neurelis, INC. | $80.62 | 2022-2025 | Valtoco |
| Novo Nordisk INC | $76.74 | 2024 | |
| Genentech USA, INC. | $66.78 | 2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $33.57 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $24.88 | 2025 | Daybue |
| Amgen INC. | $23.32 | 2020 | |
| Grt US Holding, INC. | $20.07 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.71 | 2024 | Crexont |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.